Soligenix Partners With SERB Pharmaceuticals To Supply Ricin Antigen For Ricin Toxin Poisoning Treatment
Soligenix Inc (NASDAQ: SNGX) has signed a worldwide license to supply its ricin antigen to SERB Pharmaceuticals for novel therapeutic treatment against ricin toxin poisoning.
"Beyond our own development of a heat-stable ricin vaccine (RiVax) to protect against lethal ricin poisoning, which has been supported with more than $30 million to date by the U.S. government, we felt it important to also partner with SERB in the development of its ricin therapeutic drug candidate," stated Christopher Schaber President & CEO of Soligenix.
"SERB is a leader in the field of medical countermeasures to protect the public and military forces...we are hopeful that it will assist in accelerating the development of this early-stage program," Schaber added.
SERB will leverage its broad-spectrum polyclonal antibody platform.
This platform is currently used to manufacture two of the company's currently marketed products, CroFab and DigiFab.
The antibodies will be generated using a modified form of the ricin toxin, developed by Soligenix.
The modifications have removed the protein's biological activity so that it is not toxic while still retaining its shape to trigger an effective antibody response.
Price Action: SNGX shares are up 4.84% at $0.80 during the market session on the last check Monday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
